Freedom Capital Markets has downgraded Johnson & Johnson (JNJ) to Hold from Buy, effective October 21, 2025. The current share price stands at $193.83.
This downgrade indicates a shift towards caution regarding the company's outlook, potentially reflecting concerns about competitive pressures, market conditions, or execution risks that may affect performance. Johnson & Johnson, a leading player in the pharmaceuticals industry, is headquartered in New Brunswick, New Jersey, and employs approximately 138,100 full-time staff. The company operates through two primary segments: Innovative Medicine and MedTech, focusing on areas such as immunology, oncology, and cardiovascular health.
As of November 1, 2025, the analyst consensus for Johnson & Johnson includes 6 Strong Buy, 12 Buy, and 13 Hold ratings, with no Sell or Strong Sell ratings among a total of 31 analysts. The consensus rating remains Buy.
The company recently reported in-line earnings for Q3 2025, with an EPS of $2.80, slightly above the estimate of $2.78. Upcoming earnings are scheduled for July 13, 2026, with an estimated EPS of $2.92 and revenue of $25.0 billion. Analyst ratings can evolve as new information emerges, and they should be considered alongside other factors such as company fundamentals and market trends.